Hmdb loader
Survey
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:50 UTC
Update Date2022-03-07 02:51:45 UTC
HMDB IDHMDB0014844
Secondary Accession Numbers
  • HMDB14844
Metabolite Identification
Common NameTamsulosin
DescriptionTamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate.
Structure
Data?1582753226
Synonyms
ValueSource
(-)-TamsulosinChEBI
(R)-(-)-TamsulosinChEBI
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamideChEBI
TamsulosinaChEBI
TamsulosineChEBI
TamsulosinumChEBI
FlomaxKegg
TamsulonKegg
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulphonamideGenerator
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamideHMDB
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulphonamideHMDB
YM-617HMDB
5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamideHMDB
Tamsulosin hydrochlorideHMDB
Chemical FormulaC20H28N2O5S
Average Molecular Weight408.512
Monoisotopic Molecular Weight408.171892706
IUPAC Name5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzene-1-sulfonamide
Traditional Nametamsulosin
CAS Registry Number106133-20-4
SMILES
CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
InChI Identifier
InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1
InChI KeyDRHKJLXJIQTDTD-OAHLLOKOSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Benzenesulfonamide
  • Benzenesulfonyl group
  • Phenylpropane
  • Phenoxy compound
  • Anisole
  • Phenol ether
  • Methoxybenzene
  • Alkyl aryl ether
  • Aralkylamine
  • Organosulfonic acid amide
  • Aminosulfonyl compound
  • Sulfonyl
  • Organosulfonic acid or derivatives
  • Organic sulfonic acid or derivatives
  • Secondary aliphatic amine
  • Ether
  • Secondary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Organic nitrogen compound
  • Organic oxide
  • Organopnictogen compound
  • Organosulfur compound
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point226 - 228 °C (hydrochloride salt)Not Available
Boiling PointNot AvailableNot Available
Water Solubility0.0066 g/LNot Available
LogP2.3Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.0066 g/LALOGPS
logP3.05ALOGPS
logP2.04ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)9.93ChemAxon
pKa (Strongest Basic)9.28ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.88 ŲChemAxon
Rotatable Bond Count11ChemAxon
Refractivity108.86 m³·mol⁻¹ChemAxon
Polarizability43.95 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+195.84931661259
DarkChem[M-H]-195.53431661259
DeepCCS[M+H]+194.28730932474
DeepCCS[M-H]-191.92930932474
DeepCCS[M-2H]-225.87330932474
DeepCCS[M+Na]+201.10130932474
AllCCS[M+H]+199.232859911
AllCCS[M+H-H2O]+196.632859911
AllCCS[M+NH4]+201.632859911
AllCCS[M+Na]+202.232859911
AllCCS[M-H]-194.632859911
AllCCS[M+Na-2H]-195.432859911
AllCCS[M+HCOO]-196.432859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
TamsulosinCCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O5068.6Standard polar33892256
TamsulosinCCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O3472.7Standard non polar33892256
TamsulosinCCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O3370.0Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Tamsulosin,1TMS,isomer #1CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C)=C13296.5Semi standard non polar33892256
Tamsulosin,1TMS,isomer #1CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C)=C13259.3Standard non polar33892256
Tamsulosin,1TMS,isomer #1CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C)=C14372.5Standard polar33892256
Tamsulosin,1TMS,isomer #2CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1)[Si](C)(C)C3380.0Semi standard non polar33892256
Tamsulosin,1TMS,isomer #2CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1)[Si](C)(C)C3309.3Standard non polar33892256
Tamsulosin,1TMS,isomer #2CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1)[Si](C)(C)C5035.5Standard polar33892256
Tamsulosin,2TMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C)=C1)[Si](C)(C)C3385.9Semi standard non polar33892256
Tamsulosin,2TMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C)=C1)[Si](C)(C)C3430.9Standard non polar33892256
Tamsulosin,2TMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C)=C1)[Si](C)(C)C4242.7Standard polar33892256
Tamsulosin,2TMS,isomer #2CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)=C13259.1Semi standard non polar33892256
Tamsulosin,2TMS,isomer #2CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)=C13436.6Standard non polar33892256
Tamsulosin,2TMS,isomer #2CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)=C14246.2Standard polar33892256
Tamsulosin,3TMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)=C1)[Si](C)(C)C3392.9Semi standard non polar33892256
Tamsulosin,3TMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)=C1)[Si](C)(C)C3609.5Standard non polar33892256
Tamsulosin,3TMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)=C1)[Si](C)(C)C4127.4Standard polar33892256
Tamsulosin,1TBDMS,isomer #1CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)=C13503.5Semi standard non polar33892256
Tamsulosin,1TBDMS,isomer #1CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)=C13511.8Standard non polar33892256
Tamsulosin,1TBDMS,isomer #1CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)=C14327.4Standard polar33892256
Tamsulosin,1TBDMS,isomer #2CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1)[Si](C)(C)C(C)(C)C3622.7Semi standard non polar33892256
Tamsulosin,1TBDMS,isomer #2CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1)[Si](C)(C)C(C)(C)C3513.8Standard non polar33892256
Tamsulosin,1TBDMS,isomer #2CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1)[Si](C)(C)C(C)(C)C5004.3Standard polar33892256
Tamsulosin,2TBDMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C3831.1Semi standard non polar33892256
Tamsulosin,2TBDMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C3909.1Standard non polar33892256
Tamsulosin,2TBDMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C4247.3Standard polar33892256
Tamsulosin,2TBDMS,isomer #2CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13689.8Semi standard non polar33892256
Tamsulosin,2TBDMS,isomer #2CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13884.7Standard non polar33892256
Tamsulosin,2TBDMS,isomer #2CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C14220.2Standard polar33892256
Tamsulosin,3TBDMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C4048.7Semi standard non polar33892256
Tamsulosin,3TBDMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C4262.2Standard non polar33892256
Tamsulosin,3TBDMS,isomer #1CCOC1=CC=CC=C1OCCN([C@H](C)CC1=CC=C(OC)C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1)[Si](C)(C)C(C)(C)C4149.2Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Tamsulosin GC-MS (Non-derivatized) - 70eV, Positivesplash10-0fc0-1696000000-feeed148e3d1a2085e882017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Tamsulosin GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 10V, Positive-QTOFsplash10-0a4i-0234900000-bc2e2b9eaaaeda3fce7e2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 20V, Positive-QTOFsplash10-05i0-1593100000-b0b9b35ee520544357c42016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 40V, Positive-QTOFsplash10-01b9-5931000000-a01082b9fcdb3d11e5962016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 10V, Negative-QTOFsplash10-0a4i-2322900000-a47a51f53354ebc1348d2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 20V, Negative-QTOFsplash10-0550-3907200000-6c1b7cdc5c84f0dccbf32016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 40V, Negative-QTOFsplash10-06vj-9513000000-b91e35440806c5c374f92016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 10V, Positive-QTOFsplash10-05fr-0090500000-1c851350cf0ebcbae96b2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 20V, Positive-QTOFsplash10-05i1-0090100000-b587f2fee8a0ea0159422021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 40V, Positive-QTOFsplash10-0udl-0190000000-e302ff6e9ab7b1839d492021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 10V, Negative-QTOFsplash10-0a4i-0011900000-843109d3cddf29aa626d2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 20V, Negative-QTOFsplash10-0a6r-3496200000-c3ebf3e04317201646fb2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Tamsulosin 40V, Negative-QTOFsplash10-0a4i-7975000000-15eea5b5d8ae22b42b132021-10-11Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Extracellular
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00706 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00706 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00706
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID114457
KEGG Compound IDC07124
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkTamsulosin
METLIN IDNot Available
PubChem Compound129211
PDB IDNot Available
ChEBI ID9398
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ: Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs. 2002;62(1):135-67. [PubMed:11790159 ]
  2. Dunn CJ, Matheson A, Faulds DM: Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002;19(2):135-61. [PubMed:11950378 ]
  3. Wilt TJ, Mac Donald R, Rutks I: Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2003;(1):CD002081. [PubMed:12535426 ]

Enzymes

General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide.
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular weight:
57255.585
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
General function:
Involved in monooxygenase activity
Specific function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular weight:
55768.94
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular weight:
51486.0
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Abrams P, Speakman M, Stott M, Arkell D, Pocock R: A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997 Oct;80(4):587-96. [PubMed:9352698 ]
  3. Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304. [PubMed:10503165 ]
  4. Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11. [PubMed:9352700 ]
  5. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155-67. [PubMed:8647141 ]
  6. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):145-54. [PubMed:8647140 ]
  7. Chen Y, Li H, Dong Q, Wang KJ: Blockade of alpha 1A-adrenoceptor: a novel possible strategy for male contraception. Med Hypotheses. 2009 Aug;73(2):140-1. doi: 10.1016/j.mehy.2009.02.022. Epub 2009 May 8. [PubMed:19427736 ]
  8. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular weight:
56835.4
References
  1. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758 ]
  2. Michel MC, Hanft G, Gross G: Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol. 1994 Feb;111(2):539-46. [PubMed:7911719 ]
  3. Taguchi K, Saitoh M, Sato S, Asano M, Michel MC: Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 1997 Jan;280(1):1-5. [PubMed:8996174 ]
  4. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA: Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate. 1997 Sep 15;33(1):55-9. [PubMed:9294627 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular weight:
60462.2
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR: The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol. 1997 Jan;120(2):231-8. [PubMed:9117115 ]
  3. Lowe FC: Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia. Rev Urol. 2005;7 Suppl 4:S13-21. [PubMed:16986050 ]
  4. Tomiyama Y, Tatemichi S, Tadachi M, Kobayashi S, Hayashi M, Kobayashi M, Yamazaki Y, Shibata N: [Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:225-30. [PubMed:16518087 ]
  5. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758 ]
  6. Taguchi K, Saitoh M, Sato S, Asano M, Michel MC: Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 1997 Jan;280(1):1-5. [PubMed:8996174 ]
  7. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444 ]